CABALETTA BIO, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
CABALETTA BIO, INC. (CABA) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent of -5.30% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch · last filed 2025-03-31
- CABALETTA BIO, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2024 was -5.30%.
- CABALETTA BIO, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2023 was -6.40%, a 242.22% decline from fiscal 2022.
- CABALETTA BIO, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2022 was 4.50%, a 2.27% increase from fiscal 2021.
- CABALETTA BIO, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2021 was 4.40%, a 69.23% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -5.30% 10-K · filed 2025-03-31 | |
| 2023-12-31 | -6.40% 10-K · filed 2025-03-31 | 6.40% 10-K · filed 2024-03-21 |
| 2022-12-31 | 4.50% 10-K · filed 2024-03-21 | |
| 2021-12-31 | 4.40% 10-K · filed 2023-03-16 | |
| 2020-12-31 | 2.60% 10-K · filed 2022-03-17 | |
| 2019-12-31 | 2.30% 10-K · filed 2021-03-16 | |
| 2018-12-31 | 0.60% 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |